Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KVAC
stocks logo

KVAC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Keen Vision Acquisition Corp (KVAC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Keen Vision Acquisition Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.11
Current PS
0.00
Overvalued PS
1.25
Undervalued PS
-1.02
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KVAC News & Events

Events Timeline

(ET)
2025-07-15
08:04:56
Medera, University of Kansas report first patient treated in gene therapy trial
select
2025-06-24 (ET)
2025-06-24
08:10:28
Medera, Novoheart announce collaboration with scientists at University of CA
select
2025-06-13 (ET)
2025-06-13
08:06:33
Medera, Novoheart present breakthroughs in human mini-heart platforms, therapy
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
06-24Globenewswire
Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome

  • Mini-Heart Models Development: A collaboration between Medera, Novoheart, and leading medical institutions aims to create the first human mini-heart models from stem cells of hypoplastic left heart syndrome (HLHS) patients, enhancing understanding and treatment personalization for this severe congenital heart condition.

  • Focus on Personalized Treatment: The initiative seeks to improve survival rates and quality of life for pediatric HLHS patients by identifying which individuals may benefit most from various treatments, leveraging advanced 3D bioengineered cardiac tissues that better replicate human heart function compared to traditional models.

[object Object]
Preview
9.0
06-13Globenewswire
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025

  • Presentation Highlights: Medera Inc. showcased seven presentations at the ISSCR 2025, including a significant oral presentation on their first-in-human gene therapy for heart failure, utilizing their innovative human mini-Heart technology, which supports clinical trials and regulatory approvals.

  • Regulatory Advances: The FDA has recognized Medera's human-based screening platform as an animal-free alternative in drug development, emphasizing its potential to enhance drug classification, patient-specific disease modeling, and accelerate clinical translation while aligning with new federal policies.

[object Object]
Preview
9.0
05-19Newsfilter
Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

  • Clinical Trial Results: Medera Inc. announced positive interim results from its MUSIC-HFpEF Phase 1/2a clinical trial for SRD-002, a gene therapy aimed at treating heart failure with preserved ejection fraction (HFpEF), showing a favorable safety profile and early clinical benefits in patients.

  • Significance of HFpEF: HFpEF affects approximately half of all heart failure patients globally, representing a significant unmet medical need, and the promising results from SRD-002 may provide a transformative approach to address the underlying pathophysiology of this condition.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Keen Vision Acquisition Corp (KVAC) stock price today?

The current price of KVAC is 11.75 USD — it has increased 0.43 % in the last trading day.

arrow icon

What is Keen Vision Acquisition Corp (KVAC)'s business?

Keen Vision Acquisition Corporation is a blank check company. The Company is formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses. The Company is an early-stage company and an emerging growth company. The Company has neither engaged in any operations nor generated any revenues.

arrow icon

What is the price predicton of KVAC Stock?

Wall Street analysts forecast KVAC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVAC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Keen Vision Acquisition Corp (KVAC)'s revenue for the last quarter?

Keen Vision Acquisition Corp revenue for the last quarter amounts to -248.48K USD, decreased -50.86 % YoY.

arrow icon

What is Keen Vision Acquisition Corp (KVAC)'s earnings per share (EPS) for the last quarter?

Keen Vision Acquisition Corp. EPS for the last quarter amounts to -177610.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Keen Vision Acquisition Corp (KVAC)'s fundamentals?

The market is revising No Change the revenue expectations for KVAC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 1.56%.
arrow icon

How many employees does Keen Vision Acquisition Corp (KVAC). have?

Keen Vision Acquisition Corp (KVAC) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Keen Vision Acquisition Corp (KVAC) market cap?

Today KVAC has the market capitalization of 108.09M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free